Back to top
more

Labcorp (LH)

(Real Time Quote from BATS)

$237.11 USD

237.11
162,189

+2.73 (1.17%)

Updated Nov 7, 2024 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Retain STERIS (STE) Stock For Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to its strong fiscal second-quarter results and bullish 2022 outlook.

Medtronic's (MDT) PillCam SB3 System Gets 510 (k) Clearance

by Zacks Equity Research

Medtronic's (MDT) PillCam SB3 System provides a convenient option for a contactless procedure and helps ensure that patients can access care promptly.

Abbott (ABT) Aveir System Meets Primary Pivotal Trial Endpoints

by Zacks Equity Research

Abbott's (ABT) Aveir pacing system has the potential to advance treatment for patients who need a pacemaker but where physicians are concerned about more invasive surgery.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by consistent recovery across its businesses and raised 2021 guidance.

Here's Why You Should Retain Edwards Lifesciences (EW) Stock

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) on strong third-quarter results and bullish 2021 guidance.

Omnicell (OMCL) Inks New Deal to Manage Controlled Substances

by Zacks Equity Research

Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Robust performance across the Roto-Rooter segment and sequential growth in VITAS admissions are driving the top line for Chemed (CHE).

NuVasive (NUVA) Q3 Earnings Miss Estimates, 2021 Guidance Down

by Zacks Equity Research

NuVasive (NUVA) reported lower-than-expected earnings and revenues with COVID-led headwinds and healthcare staffing shortages dampening the Q3 top-line growth.

Nevro (NVRO) Q3 Earnings Miss Estimates, Revenues Surpass

by Zacks Equity Research

Nevro (NVRO) reported wider-than-expected loss during the third quarter with a year-over-year decline in revenues across U.S. and international businesses.

Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up

by Zacks Equity Research

Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.

Sanghamitra Saha headshot

5 Stocks Likely to Give Sweet Surprises on Earnings

by Sanghamitra Saha

These top-ranked stocks are likely to beat on the bottom line in their next releases.

Is LabCorp (LH) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LH vs. COO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LH vs. COO: Which Stock Is the Better Value Option?

Will LabCorp (LH) Gain on Rising Earnings Estimates?

by Zacks Equity Research

LabCorp (LH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up

by Zacks Equity Research

LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.

LabCorp (LH) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of 42.98% and 13.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for LabCorp (LH) This Earnings Season?

by Zacks Equity Research

LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Avantor (AVTR) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Avantor (AVTR) is likely to have gained during the third quarter on the back of robust performance of its end markets.

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.

LabCorp (LH) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

LabCorp's (LH) Covance Drug Development third-quarter results are expected to reflect an increase in organic revenues in the base business.

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) third-quarter results are likely to reflect continued strength across its business segments.

Are Investors Undervaluing LabCorp (LH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LH or ALGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LH vs. ALGN: Which Stock Is the Better Value Option?